Twist Bioscience Co. (NASDAQ:TWST) CEO Sells $256,620.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 5,200 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $256,620.00. Following the transaction, the chief executive officer now owns 667,318 shares in the company, valued at approximately $32,932,143.30. This represents a 0.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Twist Bioscience Price Performance

TWST stock traded up $1.64 during midday trading on Wednesday, hitting $53.66. The stock had a trading volume of 942,522 shares, compared to its average volume of 780,335. The company’s 50-day moving average price is $48.63 and its 200 day moving average price is $46.21. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90. The firm has a market cap of $3.19 billion, a PE ratio of -14.91 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The business had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The business’s revenue for the quarter was up 24.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.75) EPS. As a group, sell-side analysts anticipate that Twist Bioscience Co. will post -2.27 EPS for the current year.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently made changes to their positions in the business. Thrivent Financial for Lutherans acquired a new stake in Twist Bioscience during the third quarter worth about $43,992,000. State Street Corp raised its stake in shares of Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after purchasing an additional 526,028 shares in the last quarter. Wellington Management Group LLP increased its stake in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after buying an additional 521,272 shares during the period. Jennison Associates LLC raised its holdings in Twist Bioscience by 80.2% during the fourth quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock worth $31,636,000 after purchasing an additional 302,884 shares in the last quarter. Finally, ARK Investment Management LLC increased its position in shares of Twist Bioscience by 4.4% during the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock valued at $260,040,000 after purchasing an additional 237,772 shares during the period.

Wall Street Analyst Weigh In

TWST has been the subject of several analyst reports. Robert W. Baird upped their target price on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday. Scotiabank raised their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the stock a “sector outperform” rating in a research report on Tuesday. TD Cowen reiterated a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Leerink Partners raised their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Finally, JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus target price of $53.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.